The excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress
October 3, 2022
Andreas Kjaer, Professor and CSO at FluoGuide presented the excellent phase I/IIa clinical data of FG001 in aggressive brain cancer data at the World Molecular Imaging Congress (WMIC).
In the phase I/IIa trial, which had Chief Surgeon Jane Skjøth-Rasmussen as Principal Investigator, the neurosurgeon collected 31 tissue samples during surgery from the 8 patients dosed with FG001, at 36 and 48 mg in the evening. This included both tissue that lit up and tissue that did not lit up. After surgery, two histopathologists evaluated the samples independently and determined if the tissue samples contained cancer or not. The histopathologists read the samples in a blinded manner, meaning that they did not know where the neurosurgeon had taken the samples or if the samples had lightened up. 100% of the biopsies that lit up during surgery contained cancer.
In the 40 patients FG001 were administered to, FG001 was shown to be safe and well-tolerated. No serious drug related adverse events were reported. Only a few (4) drug-related mild adverse events (grade 1 and 2) were reported in 3 patients out of the 40 included patients.
The presentation took place at the session ‘Curative Intent with Image-Guided Surgery’ on Friday 30 September at WMIC (abstract can be found here). Please also find the initial press release on the clinical data from 1. April 2022 here
Based on the excellent clinical data, FG001 is advanced into a phase IIb trial in aggressive brain cancer where the top line result is expected in H1 2023.
Morten Albrechtsen, CEO says: “100% is as good as it gets, and needless to say, essential particularly in brain cancer surgery”.
Furthermore, Dr. Sorel Kurbegovic presented promising pre-clinical data on FG002. The presentation took place at the session ‘Curative Intent with Image-Guided Surgery’ on Friday 30 September at WMIC.
Data on FG002 has also been published in the article entitled “IRDye800CW Labelled uPAR-Targeting Peptide for Fluorescence-Guided Glioblastoma Surgery: Preclinical Studies in Orthotopic Xenografts”. FluoGuide’s founder and CSO Andreas Kjær is senior author of the article (link to publications – see “3. FG002 in vivo study”)